Context Therapeutics, Inc. (CNTX)

Over the past six months, Context Therapeutics Inc. (CNTX) stock has experienced significant price appreciation. Analyst ratings and price targets have influenced the stock, with several analysts issuing "Buy" or "Strong Buy" ratings, though some reports indicate mixed sentiment. Financial reporting and outlook have also played a role, with the company maintaining a cash balance projected to fund operations into mid-2027, though it reported a net loss in Q3 2025 and missed quarterly EPS estimates in March 2026. Clinical pipeline updates and conference participations, where the company provided updates on its clinical programs, have also impacted the stock.

Context Therapeutics Inc. does not experience traditional demand seasonality for its products and services. The "demand" for its product candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for effective cancer treatments. The success and adoption of its products will depend on clinical efficacy, safety, and market access rather than seasonal consumer patterns.

Context Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focuses on discovering and developing precision therapies for genetically defined patient populations in oncology, particularly solid tumors. Its major product candidates are T cell engaging (TCE) bispecific antibodies, including CTIM-76, CT-95, and CT-202, designed to harness the immune system for targeted cancer eradication.

Context Therapeutics Inc. is headquartered in Philadelphia, Pennsylvania, United States. The company primarily conducts its clinical research in North America, while also laying the groundwork for potential global expansion.

Context Therapeutics' brand reputation presents a mixed picture. The company has received consistent positive analyst ratings, with a consensus of "Moderate Buy" from Wall Street analysts. However, past performance indicates a poor track record characterized by a lack of clinical progress, consistent financial losses, and significant cash burn. Analyst downgrades and missed earnings have also negatively impacted its reputation.

Context Therapeutics Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 59.33% to 62.99% of the company's stock is owned by institutional investors, insiders hold about 1.35%, and public companies and individual investors hold around 3.66% to 35.66%. Major institutional owners and shareholders include MPM Oncology Impact Management LP, Blue Owl Capital Holdings LP, and Deep Track Capital, LP.